Differential subcellular localization, expression and biosplice variant BRCA1-Î"11b

Oncogene

14, 1-16

DOI: 10.1038/sj.onc.1200924

Citation Report

#	Article	IF	CITATIONS
1	Localization of BRCA1 Gene Expression in Adult Cynomolgus Monkey Tissues. Journal of Histochemistry and Cytochemistry, 1997, 45, 1173-1188.	1.3	8
2	Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos Genes and Development, 1997, 11, 1226-1241.	2.7	484
3	BRCA1 is a cell cycle-regulated nuclear phosphoprotein. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 7138-7143.	3.3	185
4	Relationship of p215BRCA1 to tyrosine kinase signaling pathways and the cell cycle in normal and transformed cells. Oncogene, 1997, 14, 2863-2869.	2.6	25
5	BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases. Oncogene, 1997, 15, 143-157.	2.6	127
6	Abundance of BRCA1 transcripts in human cancer and lymphoblastoid cell lines carrying BRCA1 germ-line alterations., 1997, 73, 715-718.		15
7	Functional domains of the BRCA1 and BRCA2 proteins. Journal of Mammary Gland Biology and Neoplasia, 1998, 3, 403-412.	1.0	7
8	Localization of BRCA1 protein at the cellular level. Journal of Mammary Gland Biology and Neoplasia, 1998, 3, 423-429.	1.0	8
9	Expression of BRCA1 and BRCA2 in normal and neoplastic cells. Journal of Mammary Gland Biology and Neoplasia, 1998, 3, 389-402.	1.0	29
10	Developmental studies of Brca1 and Brca2 knock-out mice. Journal of Mammary Gland Biology and Neoplasia, 1998, 3, 431-445.	1.0	73
11	Conservation of function and primary structure in the BRCA1-associated RING domain (BARD1) protein. Oncogene, 1998, 17, 2143-2148.	2.6	36
12	Characterization of a carboxy-terminal BRCA1 interacting protein. Oncogene, 1998, 17, 2279-2285.	2.6	153
13	An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers. , 1998, 79, 334-342.		105
14	Estrogen upregulation of BRCA1 expression with no effect on localization. Molecular Carcinogenesis, 1998, 22, 102-109.	1.3	55
15	Functions of the BRCA1 and BRCA2 genes. Current Opinion in Genetics and Development, 1998, 8, 14-20.	1.5	91
16	Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation. Cell, 1998, 93, 165-176.	13.5	4,946
17	OVARIAN CANCER GENE THERAPY. Hematology/Oncology Clinics of North America, 1998, 12, 539-552.	0.9	14
19	Molecular Cloning, Sequence Analysis, Expression, and Tissue Distribution of Suppressin, a Novel Suppressor of Cell Cycle Entry. Journal of Biological Chemistry, 1998, 273, 361-368.	1.6	28

#	ARTICLE	IF	CITATIONS
20	A sensitive fluorescent assay for measuring the cysteine protease activity of Der p 1, a major allergen from the dust mite Dermatophagoides pteronyssinus. Journal of Clinical Pathology, 1998, 51, 222-224.	2.1	38
21	BRCA1 and BRCA2 proteins: roles in health and disease. Journal of Clinical Pathology, 1998, 51, 237-247.	2.1	55
22	Immunohistochemical retrieval of the principal HIV antigens p24, gp41, and gp120 in formalin fixed tissue: an investigation using HIV infected lymphoblasts and postmortem brain tissue from AIDS cases. Journal of Clinical Pathology, 1998, 51, 227-231.	2.1	4
23	Upregulation of ATM in sclerosing adenosis of the breast [published erratum appears in Mol Pathol 1998 Dec;51(6):342]. Journal of Clinical Pathology, 1998, 51, 224-226.	2.1	22
24	BRCA1 and BRCA2: from molecular genetics to clinical medicine Journal of Clinical Oncology, 1998, 16, 1969-1977.	0.8	156
25	Gene Therapy for Breast and Ovarian Cancer with BRCA1. Breast Disease, 1998, 10, 89-98.	0.4	7
26	Biological Functions of the BRCA1 Protein. Breast Disease, 1998, 10, 11-22.	0.4	4
27	Immunohistochemical analysis of BRCA1 expression in normal human buccal cells Oncology Reports, 1998, 5, 1071-6.	1.2	1
28	Aberrant Splicing of the TSG101 Tumor Suppressor Gene in Human Breast and Ovarian Cancers. Journal of the Society for Gynecologic Investigation, 1998, 5, 281-285.	1.9	1
29	Protein Partners of the BRCA1 Tumor Suppressor. Breast Disease, 1998, 10, 23-32.	0.4	4
30	Brcal: A Review of Structure and Putative Functions. Disease Markers, 1998, 13, 261-274.	0.6	38
31	Structure and expression of variant BRCA2a lacking the transactivation domain Oncology Reports, 1999, 6, 437.	1.2	1
32	Schizophrenia: An Epigenetic Puzzle?. Schizophrenia Bulletin, 1999, 25, 639-655.	2.3	84
33	Truncated BRCA2 is cytoplasmic: Implications for cancer-linked mutations. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 13920-13925.	3.3	140
34	Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: a correlation with other biological parameters. Histopathology, 1999, 34, 106-112.	1.6	56
35	Expression and function of BRCA1 and BRCA2 in familial and sporadic breast cancer. Histopathology, 1999, 34, 170-174.	1.6	6
36	Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nature Genetics, 1999, 21, 236-240.	9.4	383
37	Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nature Genetics, 1999, 22, 37-43.	9.4	711

#	ARTICLE	IF	CITATIONS
38	BRCA1 expression during prenatal development of the human mammary gland. Oncogene, 1999, 18, 4039-4043.	2.6	24
39	Sequence analysis of the rat Brca1 homolog and its promoter region. Mammalian Genome, 1999, 10, 19-25.	1.0	20
40	Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene., 1999, 80, 823-826.		46
41	Expression of human BRCA1 and BRCA2 proteins in lung from a fetus at 19 weeks' gestation. , 1999, 82, 771-773.		2
42	BRCA1 Partially Reverses the Transforming Activity of the ras Oncogene. Neoplasia, 1999, 1, 417-423.	2.3	1
43	Genetic Analysis of BRCA1 Function in a Defined Tumor Cell Line. Molecular Cell, 1999, 4, 1093-1099.	4.5	332
44	Is TP53 dysfunction required for BRCA1-associated carcinogenesis?. Molecular and Cellular Endocrinology, 1999, 155, 143-152.	1.6	57
45	Induction of GADD45 and JNK/SAPK-Dependent Apoptosis following Inducible Expression of BRCA1. Cell, 1999, 97, 575-586.	13.5	535
46	Positive Regulation of the BRCA1 Promoter. Journal of Biological Chemistry, 1999, 274, 8837-8843.	1.6	45
47	BRCA1 Is Phosphorylated at Serine 1497 In Vivo at a Cyclin-Dependent Kinase 2 Phosphorylation Site. Molecular and Cellular Biology, 1999, 19, 4843-4854.	1.1	102
48	Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers. International Journal of Cancer, 2000, 87, 317-321.	2.3	84
49	Differential expression and subcellular localization of murine BRCA1 and BRCA1-?11 isoforms in murine and human cell lines. International Journal of Cancer, 2000, 88, 519-524.	2.3	11
50	Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines. Molecular Carcinogenesis, 2000, 28, 236-246.	1.3	41
51	Laminin-rich extracellular matrix association with mammary epithelial cells suppresses Brca1 expression. Cell Death and Differentiation, 2000, 7, 360-367.	5.0	14
52	Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. Oncogene, 2000, 19, 1059-1064.	2.6	149
53	Expression of Brca1 and splice variant Brca1î"11 RNA levels in mouse mammary gland during normal development and tumorigenesis. Oncogene, 2000, 19, 5237-5243.	2.6	19
54	Transactivation of the p21 promoter by BRCA1 splice variants in mammary epithelial cells: evidence for both common and distinct activities of wildtype and mutant forms. Oncogene, 2000, 19, 6351-6360.	2.6	17
55	Screening of BRCA1 Mutation Using Immunohistochemical Staining with C-Terminal and N-Terminal Antibodies in Familial Ovarian Cancers. Japanese Journal of Cancer Research, 2000, 91, 399-409.	1.7	17

#	Article	IF	CITATIONS
56	Hereditary breast cancer: a review. Seminars in Cancer Biology, 2000, 10, 271-288.	4.3	47
57	Identification of a Functional Nuclear Export Sequence in BRCA1. Journal of Biological Chemistry, 2000, 275, 38589-38596.	1.6	137
58	Real-Time PCR Quantification of Full-Length and Exon 11 Spliced BRCA1 Transcripts in Human Breast Cancer Cell Lines. Biochemical and Biophysical Research Communications, 2000, 274, 73-78.	1.0	46
59	Multiple Transcripts of the Human Cu, Zn Superoxide Dismutase Gene. Biochemical and Biophysical Research Communications, 2000, 276, 52-56.	1.0	26
60	Isolation of a functional copy of the human BRCA1 gene by transformation-associated recombination in yeast. Gene, 2000, 250, 201-208.	1.0	26
61	Role of BRCAgene dysfunction in breast and ovarian cancer predisposition. Breast Cancer Research, 2000, 2, 324-30.	2.2	70
62	Expression Profiles of BRCA1 Splice Variants in Asynchronous and in G1/S Synchronized Tumor Cell Lines. Biochemical and Biophysical Research Communications, 2001, 280, 32-38.	1.0	60
63	Variation in Cancer Risks, by Mutation Position, in BRCA2 Mutation Carriers. American Journal of Human Genetics, 2001, 68, 410-419.	2.6	459
64	Predicting Splice Variant from DNA Chip Expression Data. Genome Research, 2001, 11, 1237-1245.	2.4	111
65	c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells. Oncogene, 2001, 20, 1357-1367.	2.6	58
66	A targeted mouse Brca1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage. Oncogene, 2001, 20, 2544-2550.	2.6	55
67	Tumorigenesis as a consequence of genetic instability in Brca1 mutant mice. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2001, 477, 183-189.	0.4	50
68	Molecular pathways involved in response to ionizing radiation of ID-8 mouse ovarian cancer cells expressing exogenous full-length Brca1 or truncated Brca1 mutant. International Journal of Oncology, 2001, 19, 599-607.	1.4	2
69	BRCA1 and Prostate Cancer. Cancer Investigation, 2001, 19, 396-412.	0.6	48
70	Impaired DNA Damage Response in Cells Expressing an Exon 11-Deleted Murine Brca1 Variant That Localizes to Nuclear Foci. Molecular and Cellular Biology, 2001, 21, 4005-4015.	1.1	103
71	The usefulness of antibodies to the BRCA1 protein in detecting the mutated BRCA1 gene. An immunohistochemical study. Journal of Clinical Pathology, 2001, 54, 476-480.	1.0	51
72	The Endogenous Fibroblast Growth Factor-2 Antisense Gene Product Regulates Pituitary Cell Growth and Hormone Production. Molecular Endocrinology, 2001, 15, 589-599.	3.7	54
73	Nucleocytoplasmic transfer of the NF2 tumor suppressor protein merlin is regulated by exon 2 and a CRM1-dependent nuclear export signal in exon 15. Human Molecular Genetics, 2002, 11, 2269-2278.	1.4	36

#	Article	IF	Citations
74	BARD1 Induces BRCA1 Intranuclear Foci Formation by Increasing RING-dependent BRCA1 Nuclear Import and Inhibiting BRCA1 Nuclear Export. Journal of Biological Chemistry, 2002, 277, 21315-21324.	1.6	170
75	Genome-wide detection of tissue-specific alternative splicing in the human transcriptome. Nucleic Acids Research, 2002, 30, 3754-3766.	6.5	364
76	Dominant-negative activity of a Brca1 truncation mutant: Effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. International Journal of Oncology, 2002, 20, 845.	1.4	18
77	Differential effects of n-3 and n-6 polyunsaturated fatty acids on BRCA1 and BRCA2 gene expression in breast cell lines. British Journal of Nutrition, 2002, 87, 281-289.	1.2	37
78	Loss of BRCA1Gene Expression in Breast Carcinoma. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2002, , 361-369.	0.0	0
79	Role of Immunohistochemical Detection of BRCA1 in Breast Cancer. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2002, , 371-384.	0.0	1
80	Expression of BRCA1 and BRCA2 in different tumor cell lines with various growth status. Clinica Chimica Acta, 2002, 320, 101-110.	0.5	11
81	Presence of BRCA1 and BRCA2 proteins in human milk fat globules after delivery. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2002, 1586, 50-56.	1.8	19
82	Analysis of BRCA1, TP53, and TSG101 germline mutations in German breast and/or ovarian cancer families. Cancer Genetics and Cytogenetics, 2002, 138, 120-127.	1.0	14
83	Reduced Brca1 protein expression in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced rat mammary carcinomas. Molecular Carcinogenesis, 2002, 34, 211-218.	1.3	5
84	Retroviral transduction of splice variant Brca1-Δ11 or mutant Brca1-W1777Stop causes mouse epithelial mammary atypical duct hyperplasia. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2002, 440, 261-266.	1.4	5
85	Brca1 regulates in vitro differentiation of mammary epithelial cells. Oncogene, 2002, 21, 4747-4756.	2.6	58
86	Loss of BRCA1 expression in sporadic male breast carcinoma. Breast Cancer Research and Treatment, 2002, 71, 1-7.	1.1	9
87	BRCA1 splice variants exhibit overlapping and distinct transcriptional transactivation activities. Journal of Cellular Biochemistry, 2003, 89, 120-132.	1.2	7
88	BRCA1 gene in breast cancer. Journal of Cellular Physiology, 2003, 196, 19-41.	2.0	228
89	BRCA1 expression in leukoplakia and carcinoma of the tongue. Journal of Surgical Oncology, 2003, 83, 232-240.	0.8	11
90	Novel consensus DNA-binding sequence for BRCA1 protein complexes. Molecular Carcinogenesis, 2003, 38, 85-96.	1.3	29
91	An adenoviral vector containing an arg–gly–asp (RGD) motif in the fiber knob enhances protein product levels from transgenes refractory to expression. Cancer Gene Therapy, 2003, 10, 559-570.	2.2	13

#	Article	IF	CITATIONS
92	Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice. Oncogene, 2003, 22, 528-537.	2.6	29
93	Tumor formation in mice with conditional inactivation of Brca1 in epithelial tissues. Oncogene, 2003, 22, 5415-5426.	2.6	38
94	Characterization of a Novel Breast Carcinoma Xenograft and Cell Line Derived from a BRCA1 Germ-Line Mutation Carrier. Laboratory Investigation, 2003, 83, 387-396.	1.7	43
95	BARD1 Participates with BRCA1 in Homology-Directed Repair of Chromosome Breaks. Molecular and Cellular Biology, 2003, 23, 7926-7936.	1.1	108
96	Extracellular Matrix Enhances Heregulin-Dependent BRCA1 Phosphorylation and Suppresses BRCA1 Expression through Its C Terminus. Molecular and Cellular Biology, 2003, 23, 579-593.	1.1	22
97	Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation. Journal of Medical Genetics, 2003, 40, 802-806.	1.5	70
98	A role for BRCA1 in sporadic breast cancer. British Journal of Cancer, 2003, 88, 1263-1270.	2.9	33
99	Resveratrol increases BRCA1 and BRCA2 mRNA expression in breast tumour cell lines. British Journal of Cancer, 2003, 89, 168-172.	2.9	46
100	Hereditary Breast and Ovarian Cancer Genes. , 2003, 222, 041-057.		3
101	Emerging roles of BRCA1 alternative splicing. Journal of Clinical Pathology, 2003, 56, 191-197.	2.1	117
102	DNA Damage Induces p53-dependent BRCA1 Nuclear Export. Journal of Biological Chemistry, 2004, 279, 28574-28584.	1.6	70
103	Down-Regulation of BRCA1 in Chronic Pancreatitis and Sporadic Pancreatic Adenocarcinoma. Clinical Cancer Research, 2004, 10, 3780-3787.	3.2	31
104	Refocusing on BRCA1. Nature Cell Biology, 2004, 6, 916-917.	4.6	8
105	Identification of BRCA1-IRIS, a BRCA1 locus product. Nature Cell Biology, 2004, 6, 954-967.	4.6	93
106	BRCA1 and BRCA2 in Breast Cancer Predisposition and Recombination Control. Journal of Mammary Gland Biology and Neoplasia, 2004, 9, 237-246.	1.0	6
107	Aberrations of breast cancer susceptibility genes occur early in sporadic breast tumors and in acquisition of breast epithelial immortalization. Genes Chromosomes and Cancer, 2004, 41, 214-222.	1.5	20
108	BARD1 regulates BRCA1 apoptotic function by a mechanism involving nuclear retention. Experimental Cell Research, 2004, 298, 661-673.	1.2	63
109	4 Role of Immunohistochemical Expression of BRCA1 in Ovarian Carcinoma. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2005, , 339-346.	0.0	0

#	Article	IF	CITATIONS
110	Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCA1 mRNA. Clinical Biochemistry, 2005, 38, 50-57.	0.8	21
111	A new alternative splice variant of BRCA1 containing an additional in-frame exon. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2005, 1731, 57-65.	2.4	14
112	Regulation of BRCA1, BRCA2 and BARD1 intracellular trafficking. BioEssays, 2005, 27, 884-893.	1.2	67
113	BRCA1 Gene Expression in Breast Cancer: A Correlative Study between Real-time RT-PCR and Immunohistochemistry. Journal of Histochemistry and Cytochemistry, 2005, 53, 621-629.	1.3	44
114	A microarray configuration to quantify expression levels and relative abundance of splice variants. Nucleic Acids Research, 2005, 33, e47-e47.	6.5	60
115	Evolutionary conservation analysis increases the colocalization of predicted exonic splicing enhancers in the BRCA1gene with missense sequence changes and in-frame deletions, but not polymorphisms. Breast Cancer Research, 2005, 7, R929-39.	2.2	24
116	BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Research, 2006, 34, 1416-1426.	6.5	483
117	A truncated splice variant of human BARD1 that lacks the RING finger and ankyrin repeats. Cancer Letters, 2006, 233, 108-116.	3.2	27
118	Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. Oncogene, 2006, 25, 5885-5897.	2.6	221
119	BRCA1 and BRCA2: The genetic testing and the current management options for mutation carriers. Critical Reviews in Oncology/Hematology, 2006, 57, 1-23.	2.0	54
120	SEL1L a multifaceted protein playing a role in tumor progression. Journal of Cellular Physiology, 2006, 208, 23-38.	2.0	36
121	BRCA1-associated complexes: new targets to overcome breast cancer radiation resistance. Expert Review of Anticancer Therapy, 2006, 6, 187-196.	1.1	8
122	Hyperplasia and Spontaneous Tumor Development in the Gynecologic System in Mice Lacking the BRCA1-Δ11 Isoform. Molecular and Cellular Biology, 2006, 26, 6983-6992.	1.1	33
123	Familial Breast/Ovarian Cancer and <i>BRCA1/2</i> Genetic Screening: The Role of Immunohistochemistry as an Additional Method in the Selection of Patients. Journal of Histochemistry and Cytochemistry, 2007, 55, 1105-1113.	1.3	23
124	Pathophysiological Roles of ASK1-MAP Kinase Signaling Pathways. BMB Reports, 2007, 40, 1-6.	1.1	173
125	Expression Patterns of the BRCA1 Splicing Variants in Canine Normal Tissues and Mammary Gland Tumors. Journal of Veterinary Medical Science, 2007, 69, 587-592.	0.3	5
126	Subcellular localization of ATBF1 regulates MUC5AC transcription in gastric cancer. International Journal of Cancer, 2007, 121, 241-247.	2.3	27
127	BRCA1a has antitumor activity in TN breast, ovarian and prostate cancers. Oncogene, 2007, 26, 6031-6037.	2.6	34

#	Article	IF	CITATIONS
128	Oncogenes and tumour suppressors take on centrosomes. Nature Reviews Cancer, 2007, 7, 911-924.	12.8	277
129	Loss of nuclear BRCA1 protein staining in normal tissue cells derived from BRCA1 and BRCA2 mutation carriers. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 619, 104-112.	0.4	6
130	Cloning and functional identification of two novel BRCA1 splicing variants. Biochemistry (Moscow), 2008, 73, 1214-1223.	0.7	3
131	Inherited breast cancer: an emerging picture. Clinical Genetics, 1998, 54, 447-458.	1.0	32
132	Expression of BRCA1 protein in breast cancer and its prognostic significance. Human Pathology, 2008, 39, 857-865.	1.1	133
134	IGF Signaling Pathway as a Selective Target of Familial Breast Cancer Therapy. Current Molecular Medicine, 2008, 8, 727-740.	0.6	7
135	Aberrant RNA splicing and its functional consequences in cancer cells. DMM Disease Models and Mechanisms, 2008, $1, 37-42$.	1.2	99
136	A novel mechanism whereby BRCA1/1a/1b fine tunes the dynamic complex interplay between SUMO-dependent/independent activities of Ubc9 on E2-induced ERα activation/repression and degradation in breast cancer cells. International Journal of Oncology, 2009, 34, 939-49.	1.4	21
137	Impaired Skin and Mammary Gland Development and Increased γ-Irradiation–Induced Tumorigenesis in Mice Carrying a Mutation of S1152-ATM Phosphorylation Site in Brca1. Cancer Research, 2009, 69, 9291-9300.	0.4	18
138	Mitochondrial localization, ELKâ€1 transcriptional regulation and growth inhibitory functions of BRCA1, BRCA1a, and BRCA1b proteins. Journal of Cellular Physiology, 2009, 219, 634-641.	2.0	41
139	Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Molecular Cancer, 2009, 8, 48.	7.9	89
140	Mouse models of uterine corpus tumors clinical significance and utility. Frontiers in Bioscience - Elite, 2010, E2, 882-905.	0.9	13
141	MYC and Breast Cancer. Genes and Cancer, 2010, 1, 629-640.	0.6	275
142	The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells. Cancer Cell International, 2011, 11, 29.	1.8	20
143	Ubc9 mediates nuclear localization and growth suppression of BRCA1 and BRCA1a proteins. Journal of Cellular Physiology, 2011, 226, 3355-3367.	2.0	33
144	A Conditional Mouse Model for Measuring the Frequency of Homologous Recombination Events <i>In Vivo</i> in the Absence of Essential Genes. Molecular and Cellular Biology, 2011, 31, 3593-3602.	1.1	12
146	Evolutionary Constraint Helps Unmask a Splicing Regulatory Region in BRCA1 Exon 11. PLoS ONE, 2012, 7, e37255.	1.1	17
147	Identification of a non-canonical nuclear localization signal (NLS) in BRCA1 that could mediate nuclear localization of splice variants lacking the classical NLS. Cellular and Molecular Biology Letters, 2013, 18, 284-96.	2.7	16

#	Article	IF	CITATIONS
148	Mouse models of BRCA1 and their application to breast cancer research. Cancer and Metastasis Reviews, 2013, 32, 25-37.	2.7	57
149	The functional role of the novel biomarker karyopherin $\hat{l}\pm 2$ (KPNA2) in cancer. Cancer Letters, 2013, 331, 18-23.	3.2	104
150	GT198 Splice Variants Display Dominant-Negative Activities and Are Induced by Inactivating Mutations. Genes and Cancer, 2013, 4, 26-38.	0.6	20
151	BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. Journal of Experimental Medicine, 2013, 210, 1529-1544.	4.2	239
152	Evaluation of a 5-Tier Scheme Proposed for Classification of Sequence Variants Using Bioinformatic and Splicing Assay Data: Inter-Reviewer Variability and Promotion of Minimum Reporting Guidelines. Human Mutation, 2013, 34, 1424-1431.	1.1	67
153	BRCA1 Exon 11, a CERES (Composite Regulatory Element of Splicing) Element Involved in Splice Regulation. International Journal of Molecular Sciences, 2014, 15, 13045-13059.	1.8	36
154	BRCA1 is a novel regulator of metabolic function in skeletal muscle. Journal of Lipid Research, 2014, 55, 668-680.	2.0	27
155	Quantitative imaging of single mRNA splice variants in living cells. Nature Nanotechnology, 2014, 9, 474-480.	15.6	148
156	Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas. Pathology Research and Practice, 2014, 210, 533-540.	1.0	17
157	Characterization of three alternative transcripts of the BRCA1 gene in patients with breast cancer and a family history of breast and/or ovarian cancer who tested negative for pathogenic mutations. International Journal of Molecular Medicine, 2015, 35, 950-956.	1.8	16
158	BRCA1 mislocalization associated with breast carcinogenesis and poor prognosis in Taiwanese women. European Journal of Cancer Prevention, 2015, 24, 407-415.	0.6	0
159	KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer. British Journal of Cancer, 2015, 112, 1929-1937.	2.9	55
160	BRCA1 and BARD1 colocalize mainly in the cytoplasm of breast cancer tumors, and their isoforms show differential expression. Breast Cancer Research and Treatment, 2015, 153, 669-678.	1.1	11
161	The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Research, 2016, 76, 2778-2790.	0.4	208
162	Targeted delivery of bio-synthetic lycopene by the bacterial carrier. Journal of the Taiwan Institute of Chemical Engineers, 2016, 59, 91-97.	2.7	6
163	Differential expression of parental alleles of BRCA1 in human preimplantation embryos. European Journal of Human Genetics, 2017, 25, 37-42.	1.4	2
164	Malignant pericytes expressing GT198 give rise to tumor cells through angiogenesis. Oncotarget, 2017, 8, 51591-51607.	0.8	22
165	Overactive BRCA1 Affects Presenilin 1 in Induced Pluripotent Stem Cell-Derived Neurons in Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 62, 175-202.	1.2	36

#	ARTICLE	IF	CITATIONS
166	Identification of FUBP1 as a Long Tail Cancer Driver and Widespread Regulator of Tumor Suppressor and Oncogene Alternative Splicing. Cell Reports, 2019, 28, 3435-3449.e5.	2.9	32
167	BRCA1—No Matter How You Splice It. Cancer Research, 2019, 79, 2091-2098.	0.4	16
168	Oncoprotein GT198 vaccination delays tumor growth in MMTV-PyMT mice. Cancer Letters, 2020, 476, 57-66.	3.2	6
169	BRCA1 Antibodies Matter. International Journal of Biological Sciences, 2021, 17, 3239-3254.	2.6	4
170	Untangling the crosstalk between BRCA1 and R-loops during DNA repair. Nucleic Acids Research, 2021, 49, 4848-4863.	6.5	21
171	Dual Modulators of p53 and Cyclin D in ER Alpha Signaling by Albumin Nanovectors Bearing Zinc Chaperones for ER-positive Breast Cancer Therapy. Mini-Reviews in Medicinal Chemistry, 2021, 21, 792-802.	1.1	6
172	Altered regulation of <i>BRCA1</i> exon 11 splicing is associated with breast cancer risk in carriers of <i>BRCA1</i> pathogenic variants. Human Mutation, 2021, 42, 1488-1502.	1.1	7
173	The Role of Tumor Suppressor Genes in Breast Cancer Progression. , 1999, , 119-132.		1
174	Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancersa *†. Journal of the Society for Gynecologic Investigation, 1998, 5, 281-285.	1.9	13
175	Differential effects of n-3 and n-6 polyunsaturated fatty acids on BRCA1 and BRCA2 gene expression in breast cell lines. British Journal of Nutrition, 2002, 87, 281-9.	1.2	23
176	Familial Breast-Ovarian Cancer Syndromes. Clinical Obstetrics and Gynecology, 1998, 41, 157-166.	0.6	19
177	Methylation of the Tumor Suppressor Protein, BRCA1, Influences Its Transcriptional Cofactor Function. PLoS ONE, 2010, 5, e11379.	1.1	73
178	A novel Ubc9 -dependent pathway regulates SIRT1- ER- $\hat{l}\pm$ Axis and BRCA1- associated TNBC lung metastasis. Integrative Molecular Medicine, 2017, 4, .	0.3	6
179	A Novel Pathway that Links Caveolin-1 Down-Regulation to BRCA1 Dysfunction in Serous Epithelial Ovarian Cancer Cells. Enliven Challenges in Cancer Detection and Therapy, 2014, 01, .	0.5	4
180	The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers. Frontiers in Bioscience - Landmark, 2014, 19, 605.	3.0	147
181	Alternative Splicing of Breast Cancer Associated Gene BRCA1 from Breast Cancer Cell Line. BMB Reports, 2007, 40, 15-21.	1.1	21
183	Biological Functions of the BRCA1 and BRCA2 Proteins. , 1999, , 225-246.		1
184	BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells. International Journal of Chronic Diseases & Therapy, 0, , 31-38.	0.0	7

#	Article	IF	CITATIONS
185	BRCA1 proteins regulate growth of ovarian cancer cells by tethering Ubc9. American Journal of Cancer Research, 2012, 2, 540-8.	1.4	8
188	BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells. , 2016, 2, 31-38.		6
189	Quantification of mRNA in Single Cells Based on Dimerization-Induced Photoluminescence Nonblinking of Quantum Dots. Analytical Chemistry, 2022, 94, 12407-12415.	3.2	3